Named the 2022 Top Emerging Company at BIO International, SiVEC Biotechnologies has developed BactPac™, a drug delivery platform to enable the next generation of nucleic acid and gene therapies. BactPac overcomes the limitations of viral and nonviral delivery systems and is a complete solution for all-in-one therapeutic payload production and targeted delivery. Visit us at www.sivecbiotechnologies.com

Immunyx is pioneering new approaches to immune modulation using targeted nanoparticles to change the function of neutrophils. Our team of world experts in neutrophil biology and nanoparticle development are using cutting edge tools to bring new therapies to patients across a broad spectrum of diseases. For more info please visit www.immunyx.com

Pharmacin is a global biotechnology company with a proprietary formulation technology, SpraySol™. This IP protected technology is a scalable, multicomponent amorphous solid dispersion formulation combined with spray drying. The technology, successfully advanced in the clinic, can be applied to early phase NCE’s and 505(b)(2) candidates. To learn more visit www.pharmacin.com

NovaXS Biotech is a smart medical device startup developing the next generation of smart needle-free drug delivery platform that simplifies the drug self-administration process, improves the medication adherence and optimizes the remote treatment outcomes.To learn more visit www.novaxs.co

Adare Pharma Solutions is a global technology-driven CDMO providing end-to-end integrated services, from product development through commercial manufacturing and packaging, with expertise in complex oral formulations. Our specialized technology platforms provide taste masking, controlled release, solubility enhancement, and patient-centric dosing solutions. To learn more, please visit www.adarepharmasolutions.com

Nosis Bio develops cell-targeted delivery vehicles for the extrahepatic delivery of genetic medicines. Nosis delivery vehicles have been validated for functional delivery to multiple tissue and cell types and are compatible with both systemic and local routes of administration. Nosis partners with some of the world’s leading biotechs to accelerate delivery to novel tissues and develops their own internal pipeline of therapeutics. To learn more, please visit www.nosisbio.com

OxSonics is a pioneering clinical-stage company on a mission to transform cancer treatment with its breakthrough SonoTran® technology, utilising Innovative proprietary sonosensitive particles, co-administered with anti-cancer drugs, and “activated” by a novel ultrasound device. This enhances the delivery of oncology drugs into solid tumours, improving efficacy and/or reducing off-target toxicity. To learn more please visit: https://oxsonics.com/

Bionaut: Revolutionizing drug delivery to the brain. Bionaut is a global biotechnology and drug delivery company dedicated to pioneering innovative solutions for brain-targeted therapies. Our cutting-edge precision drug delivery platform enables the accurate, safe, and effective administration of treatments to challenging brain regions for a diverse range of therapeutics. Backed by robust pre-clinical safety data and poised for upcoming 2024 clinical trials, Bionaut is seeking partnerships with forward-thinking pharmaceutical industry pioneers to join our mission. Together, we can unravel the complexities of localized brain conditions and transform neurological care. Join us at the conference and learn more about our mission at www.bionautlabs.com 

EXACT Therapeutics is a clinical stage biotech company with a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT is a unique approach to ultrasound-mediated, targeted delivery of advanced therapeutics, with the potential to significantly amplify therapeutic delivery across a multitude of indications including oncology and neurological conditions For more information, visit https://exact-tx.com/

H&T PHopewell Therapeutics is discovering and developing the next generation of tissue-targeted lipid nanoparticles (ttLNPs) to bring genomic medicines to patients. Leveraging its robust IP portfolio and expansive ionizable lipid library, Hopewell is developing an internal pipeline targeting lung diseases while pursuing partnerships in oncology, infectious diseases, rare genetic diseases, and neurology. To learn more visit www.hopewell-tx.com

Rip Road develops and manages companion applications for biologics and medication delivery devices. We have pioneered a configurable platform for Software as Medical Device (SaMD) companion apps tailored for biologic medications. We are dedicated to elevating the patient experience, optimizing adherence, and building digital ecosystems for a connected device world. To learn more please visit: https://riproad.com/

EdgeOne Medical is the Contract Development Organization that specializes in supporting device development and testing programs for combination products for 10 of the top 20 global pharma and the companies they acquire. Utilizing their proprietary EdgeOne Labs and their proven Edgineering method, EdgeOne Medical is considered to be the most technically advanced and reliable partner for ensuring device programs overcome challenges, get on the market and stay on the market. To learn more, please visit www.edgeonemedical.com